Topics:

Noladex Gets Expanded Indications

Noladex Gets Expanded Indications

ROCKVILLE, Md—The FDA has approved two new indications for Zeneca’s tamoxifen (Nolvadex): For reducing the incidence of breast cancer in high-risk women, and for the reduction of contralateral breast cancer. In addition, data from clinical trials that support 5 years of adjuvant Nolvadex for breast cancer patients were added to the Nolvadex label.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.